免疫检查点抑制剂相关心肌炎诊疗进展  

Advances in the management of immune checkpoint inhibitor-associated myocarditis

作　　者：李泞甫 李智可 陈旭澜 皈燕[1] LI Ningfu;LI Zhike;CHEN Xulan;GUI Yan(Department of Oncology,Affiliated Hospital of North Sichuan Medical College,Nanchong,Sichuan,637000,China;Department of Clinical Medicine, North Sichuan Medical College)

机构地区：[1]川北医学院附属医院肿瘤科,四川南充637000 [2]川北医学院临床医学系

出　　处：《临床心血管病杂志》2024年第3期182-187,共6页Journal of Clinical Cardiology

基　　金：国家自然科学基金(No:20SXQT0329);南充市市校合作科研专项(No:20SXQT0254、20SXQT0071)。

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitor,ICI)是肿瘤治疗的一大突破,在临床应用日益广泛。ICI相关心肌炎是ICI药物的罕见不良反应之一,病死率较高。尽管国内外均报道了该不良反应的治疗经验和指南,但部分医生在临床工作中仍存在认知不足、监管评估方案缺乏等问题。故本文对ICI相关心肌炎发病机制、诊断、治疗策略进行综述,以提高肿瘤科及心脏科医师的认识。Immune checkpoint inhibitors(ICI) are a major breakthrough in oncology treatment and are increasingly used in clinical practice.ICI-associated myocarditis is one of the rare adverse reactions to ICI drugs,with a high mortality rate.Guidelines for treating this adverse reaction have been written both domestically and internationally at home and abroad.However,there is still a lack of awareness and reliable regulatory assessment protocols in clinical work.Therefore,this article reviews the pathogenesis,diagnosis,and treatment strategies of ICI-associated myocarditis in order to raise the awareness of oncologists and cardiologists.

关 键 词：心肌炎 免疫检查点抑制剂 

分 类 号：R542.2[医药卫生—心血管疾病]